GSK's long-acting injection beats Truvada in HIV prevention trial

GlaxoSmithKline said an injection every other month of its cabotegravir drug was shown to avert an HIV infection more effectively than Gilead's daily Truvada pill, potentially giving its ViiV unit a foothold in HIV prevention.

Source: Reuters: Health - May 18, 2020 Category: Consumer Health News Tags: healthNews Source Type: news